Effect Of Tamoxifen On Plasma Lipid Profile In Patients Of Breast Cancer

Area of Science:

• Oncology
• Cardiovascular Health
• Pharmacology

Background:

• Breast cancer patients often face treatment-related side effects.
• Tamoxifen is a common endocrine therapy for breast cancer.
• Evaluating Tamoxifen's impact on lipid profiles is crucial for patient management.

Purpose of the Study:

• To assess the effects of Tamoxifen on plasma lipid profiles in breast cancer patients.
• To determine changes in total cholesterol, triglycerides, HDL, and LDL levels.
• To evaluate the potential cardiovascular benefits associated with Tamoxifen treatment.

Main Methods:

• A longitudinal study involving 88 female breast cancer patients aged 26-66 years.
• Plasma lipid profiles were measured at baseline, 3 months, and 6 months post-Tamoxifen initiation.
• Measurements included total cholesterol, triglycerides, HDL, and LDL levels, analyzed using SPSS.

Main Results:

• Significant reductions in total cholesterol (32.29 mg/dl) and LDL (24.11 mg/dl) were observed at 6 months (p<0.05).
• Triglyceride levels significantly increased by 42.19 mg/dl at 6 months (p<0.05).
• No significant changes in HDL levels were noted at 3 or 6 months.

Conclusions:

• Tamoxifen treatment led to significant reductions in total cholesterol and LDL levels over six months.
• These findings suggest Tamoxifen may positively influence lipid metabolism.
• Tamoxifen's lipid-modifying effects could potentially reduce cardiovascular event risk in breast cancer patients.